N-BOC-环丙胺 | 132844-48-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酰胺
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-BOC-环丙胺
• 中文别名: N-Boc-环丙胺
• 英文名称: tert-butyl cyclopropylcarbamate
• 英文别名: N-Boc-cyclopropylamine；tert-butyl N-cyclopropylcarbamate
• CAS: 132844-48-5
• 化学式: C₈H₁₅NO₂
• mdl: MFCD09701238
• 分子量: 157.213
• InChiKey: WFFGQLYKMWGXMU-UHFFFAOYSA-N

物化性质

• 沸点：
  228.6±7.0 °C(Predicted)
• 密度：
  1.01±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Boc-cyclopropylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Boc-cyclopropylamine
CAS number: 132844-48-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H15NO2
Molecular weight: 157.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

以氯乙酮为起始物料，经过一系列化学反应制备目标化合物 N-BOC-环丙胺。具体步骤包括：硼氢化钠还原羰基、Wittig-Horner-Wadsworth 环丙烷化反应、水解、与氯甲酸乙酯反应形成酸酐，再与叠氮化钠反应生成酰基叠氮化合物，最后通过 curtis 重排生成环丙氨，并经 Boc 保护得到 N-BOC-环丙胺。其合成反应式如下图所示：

反应信息

• 作为反应物：
  描述：

  N-BOC-环丙胺 在 吡啶 、 nitrosonium tetrafluoroborate 作用下， 以 乙腈 为溶剂， 反应 2.83h， 以26%的产率得到1,1-dimethylethyl cyclopropyl(nitroso)carbamate
  参考文献：
  名称：

  Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase

  摘要：

  本文提供了以下式(I)的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。

  公开号：

  US20070049632A1
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 环丙胺 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 N-BOC-环丙胺
  参考文献：
  名称：

  N -Boc N-烷基环丙胺的锂取代

  摘要：

  据报道，在N -Boc N-烷基环丙基胺的α和β位置发生了一系列锂取代反应。在N-乙基和N-甲基衍生物6和7中，环丙烷环是锂化的优选位置，但是N-烯丙基和N-苄基衍生物8和9在亚甲基处进行锂化。如10、15和21反应所示，如果α位被封端或β位被苯基取代激活，则会观察到环丙胺环β位的锂基化。。α和β锂化均可用于锂化环化反应中，以提供双环螺或内稠合的N- Boc胺15、16和25。用s -BuLi /（-）-天冬氨酸随后用三甲基氯硅烷对N -Boc-4-甲苯磺酰哌啶30进行锂化，得到N -Boc氮杂双环[3.1.0]己烷32，其对映体过量范围为18-55％。两个β-甲氧基甲氧基取代的N - Boc环丙胺18和26可以参与与四氰基乙烯的正式[3 + 2]环加成反应，得到高度取代的环戊烷。

  DOI：

  10.1016/0040-4020(96)00736-3

文献信息

• [EN] 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDINE-3-ONE COMPOUNDS AS INHIBITORS OF WEE-1 KINASE<br/>[FR] COMPOSÉS DE 1,2-DIHYDRO-3 H-PYRAZOLO [3,4-D] PYRIMIDINE-3-ONE UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE WE -1
  申请人：NEWAVE PHARMACEUTICAL INC

  公开号：WO2019165204A1

  公开（公告）日：2019-08-29

  The disclosure includes compounds of Formula (I) wherein Q, R1, R2, and m are defined herein. Also disclosed is a method for treating a neoplastic disease with these compounds.

  披露的内容包括式(I)的化合物，其中Q、R1、R2和m在此处被定义。还披露了一种使用这些化合物治疗恶性肿瘤疾病的方法。
• Pyridazinones as antagonists of alpha4 integrins
  申请人：Barbay Kent

  公开号：US20050192279A1

  公开（公告）日：2005-09-01

  The present invention relates to certain novel compounds of Formula (I): methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of integrin mediated disorders.

  本发明涉及某些化合物的新颖结构，其化学式为（I）：制备这些化合物的方法，组合物，中间体及其衍生物以及用于治疗整合素介导的疾病。
• [EN] N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT<br/>[FR] COMPOSÉ DE N-(1H-IMIDAZOL-2-YL)BENZAMIDE ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT EN TANT QUE PRINCIPE ACTIF
  申请人：KAINOS MEDICINE INC

  公开号：WO2021066559A1

  公开（公告）日：2021-04-08

  N-(1H-imidazol-2-yl)benzamide compound of formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvate, or a stereoisomer thereof which is a novel compound exhibiting excellent inhibitory activity against IRAK-4, can be used without side effects for efficient prevention and treatment of diseases mediated by IRAK-4 receptors, particularly autoimmune diseases or lymphomas.

  N-(1H-咪唑-2-基)苯甲酰胺化合物的化学式(I)，或其药学上可接受的盐、前药、溶剂合物或立体异构体，是一种新型化合物，表现出对IRAK-4的优异抑制活性，可用于高效预防和治疗由IRAK-4受体介导的疾病，特别是自身免疫疾病或淋巴瘤，且无副作用。
• [EN] AZAINDAZOLES<br/>[FR] AZAINDAZOLES
  申请人：GLAX0SMITHKLINE LLC

  公开号：WO2013039988A1

  公开（公告）日：2013-03-21

  Herein are disclosed azaindazoles of formula (I), (I), where the various groups are defined herein, and which are useful for treating cancer.

  这里公开了公式(I)、(I)的氮杂吲唑，其中各团簇在本发明中定义，并且用于治疗癌症。
• Sulfonamidocarboxamides
  申请人：Hoffmann-La Roche Inc.

  公开号：US05405854A1

  公开（公告）日：1995-04-11

  Sulfonamidocarboxamides of the formula ##STR1## wherein A, M, Q, X and Y have the significance given in the description, as well as hydrates, solvates and salts thereof, which inhibit thrombin-induced blood platelet aggregation and clotting of fibrinogen in plasma, as described. The compounds of formula I can be prepared by amidination of a cyclic amino group standing for grouping X or by C(O)N(Q) amide formation.

  翻译结果如下： 公式##STR1##中的磺酰氨基甲酰胺，其中A、M、Q、X和Y的含义如描述中所述，以及它们的 hydrates（水合物）、solvates（溶剂合物）和盐，这些化合物能抑制凝血酶诱导的血小板聚集和血浆中纤维蛋白原的凝固，如所述。公式I的化合物可以通过对代表X基团的环状氨基进行酰胺化反应，或者通过C(O)N(Q)酰胺形成来制备。